Cellular Biomedicine Group (CBMG) has raised $120 million in series A funding, with investors including AstraZeneca, after delisting from the Nasdaq in February 2021.
The financing will be used to accelerate clinical development of the China/US-based company’s immuno-oncology platform.
CBMG’s pipeline includes:
The funding will also support the development of a stem cell platform, including the treatment of acute respiratory distress syndrome (ARDS) using allogeneic human adipose mesenchymal stem cell exosomes and extracellular vesicles. The company also has phase II trials underway for two therapies targeting knee osteoarthritis.